secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xenon Pharmaceuticals Inc. (XENE)
CIK:        0001582313
Form:       8-K
Filed at:   2023-11-30T23:59:59+00:00
Accession:  0000950170-23-067040
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xenon Pharmaceuticals raises ~$281.6M in underwritten public offering of shares and pre-funded warrants
--------------------------------------------------------------------------------

- Net proceeds ~$281.6M from sale of 8,461,542 common shares and 769,230 pre-funded warrants at $32.50 per share/warrant.
- Underwriters: J.P. Morgan, Jefferies, BofA Securities, Stifel, and RBC Capital Markets.
- Underwriters granted 30-day option to purchase up to an additional 1,384,615 common shares.
- Pre-funded warrants exercisable at $0.0001 per share, with 4.99% beneficial ownership limitation (adjustable to 19.99%).
- Offering made under existing shelf registration statement (Oct 2021); underwriting agreement dated November 29, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1582313/000095017023067040/0000950170-23-067040-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1582313/000095017023067040/xene-20231129.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-067040

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer